Maravai LifeSciences Holdings Inc. Class A Common Stock vs SkyWest Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while SkyWest Inc trades at $90.69 (market cap $3.67B). The key difference: SkyWest Inc is far larger — about 3.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SkyWest Inc for 8 Days on average.
| MRVI | SKYW | |
|---|---|---|
Market Cap | $977.37M | $3.67B |
Volume | 2,742,564 | 188,631 |
Sector | Health | Industrials |
52-Week High | $9.00 | $115.94 |
52-Week Low | $2.83 | $78.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $1.08B | $5.45B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SkyWest (SKYW) trades at $94.52, down 0.53% with a bearish technical signal despite positive analyst sentiment. The stock shows mixed earnings performance with a recent Q1 2026 beat but Q2 2026 miss, while maintaining solid fundamentals including a 9.78% net income margin and attractive valuation at 9.39 P/E. Recent news highlights fleet modernization efforts and expanding flying agreements as growth catalysts amid cost pressures.
The stock presents a compelling value opportunity with 58.8% analyst buy ratings and $112 consensus target, offering 18.5% upside potential. However, technical weakness and executive stock sales create near-term headwinds. Long-term prospects remain positive driven by operational improvements and strategic partnerships, though investors should monitor cost management and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →